{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:48:39Z","timestamp":1768344519425,"version":"3.49.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018883","name":"Maurice Wilkins Centre for Molecular Biodiscovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>We hypothesized that people with type 2 diabetes who generally have high insulin resistance, such as people of M\u0101ori\/Pacific ethnicity, and those with obesity and\/or hypertriglyceridemia (OHTG), would have greater glucose-lowering by pioglitazone (an insulin sensitizer) versus vildagliptin (an insulin secretagogue).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomised, open-label, two-period crossover trial was conducted in New Zealand. Adults with type 2 diabetes, HbA1c&amp;gt;58mmol\/mol (&amp;gt;7.5%), received 16 weeks of either pioglitazone (30mg) or vildagliptin (50mg) daily, then switched to the other medication over for another 16 weeks of treatment. Differences in HbA1c were tested for interaction with ethnicity or OHTG, controlling for baseline HbA1c using linear mixed models. Secondary outcomes included weight, blood pressure, side-effects and diabetes treatment satisfaction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>346 participants were randomised (55% M\u0101ori\/Pacific) between February 2019 to March 2020. HbA1c after pioglitazone was lower than after vildagliptin (mean difference -4.9mmol\/mol [0.5%]; 95% CI -6.3, -3.5; p&amp;lt;0.0001). Primary intention-to-treat analysis showed no significant interaction effect by M\u0101ori\/Pacific vs other ethnicity (1.5mmol\/mol [0.1%], 95% CI -0.8, 3.7), and per-protocol analysis (-1.2mmol\/mol [0.1%], 95% CI -4.1, 1.7). An interaction effect (-4.7mmol\/mol [0.5%], 95% CI -8.1, -1.4) was found by OHTG status. Both treatments generated similar treatment satisfaction scores, although there was greater weight gain and greater improvement in lipids and liver enzymes after pioglitazone than vildagliptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Comparative glucose-lowering by pioglitazone and vildagliptin is not different between M\u0101ori\/Pacific people compared with other New Zealand ethnic groups. Presence of OHTG predicts greater glucose lowering by pioglitazone than vildagliptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>www.anzctr.org.au<\/jats:uri>, identifier (ACTRN12618001907235).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1091421","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T15:07:29Z","timestamp":1673363249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Rebecca","family":"Brandon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui Qian","family":"Yeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ry","family":"Tweedie-Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Smallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry A.","family":"Macaskill-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah J.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Moffitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Merry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Nehren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennie Harr\u00e9","family":"Hindmarsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan Patricia","family":"Leask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony R.","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Orr-Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinki","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dci20-0022","article-title":"Precision medicine in diabetes: A consensus report from the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"43","author":"Chung","year":"2020","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan","year":"2020","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1539","article-title":"Differing effects of metformin on glycemic control by race-ethnicity","volume":"99","author":"Williams","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2576","article-title":"Efficacy of acarbose in different geographical regions of the world: Analysis of a real-life database","volume":"31","author":"Weng","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1827","article-title":"Precision medicine in type 2 diabetes: Clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy","volume":"41","author":"Dennis","year":"2018","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0344","article-title":"Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: A framework for evaluating stratification using routine clinical and individual trial data","volume":"41","author":"Dennis","year":"2018","journal-title":"Diabetes Care"},{"key":"B8","first-page":"U2800","article-title":"Serum lipid levels for a multicultural population in Auckland, new Zealand: results from the diabetes heart and health survey (DHAH) 2002-2003","volume":"120","author":"Gentles","year":"2007","journal-title":"N Z Med J"},{"key":"B9","unstructured":"Annual data explorer 2020\/2021: New Zealand health survey2021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30412-5","article-title":"Ethnic differences in mortality and hospital admission rates between m\u0101ori, pacific, and European new Zealanders with type 2 diabetes between 1994 and 2018: A retrospective, population-based, longitudinal cohort study","volume":"9","author":"Yu","year":"2021","journal-title":"Lancet Glob Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.10.016","article-title":"Defining drug response for stratified medicine","volume":"22","author":"Lonergan","year":"2017","journal-title":"Drug Discovery Today"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e036518","DOI":"10.1136\/bmjopen-2019-036518","article-title":"Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: Predicting which one is right here (WORTH) study protocol","volume":"10","author":"Yeu","year":"2020","journal-title":"BMJ Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.279","article-title":"Patient perceptions of diabetes and diabetes therapy: Assessing quality of life","volume":"18","author":"Bradley","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4378","article-title":"CONSORT 2010 statement: Extension to randomised crossover trials","volume":"366","author":"Dwan","year":"2019","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3620","article-title":"A thrifty variant in CREBRF strongly influences body mass index in samoans","volume":"48","author":"Minster","year":"2016","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4623-1","article-title":"Discordant association of the CREBRF rs373863828 a allele with increased BMI and protection from type 2 diabetes in Maori and pacific (Polynesian) people living in Aotearoa\/New Zealand","volume":"61","author":"Krishnan","year":"2018","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-5552-x","article-title":"The CREBRF diabetes-protective rs373863828-a allele is associated with enhanced early insulin release in men of m\u0101ori and pacific ancestry","volume":"64","author":"Burden","year":"2021","journal-title":"Diabetologia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1903","article-title":"Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia","volume":"30","author":"Deeg","year":"2007","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01262.x","article-title":"Cardiovascular risk and thiazolidinediones\u2013what do meta-analyses really tell us","volume":"12","author":"Schernthaner","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.46.4.507","article-title":"PPAR-gamma: Adipogenic regulator and thiazoledinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.055","article-title":"The PPARG agonist pioglitazone represses inflammation in a PPARG alpha-dependent manner: in vitro and in vivo in mice","volume":"52","author":"Orasanu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e04278","DOI":"10.1136\/bmjopen-2020-042784","article-title":"TriMaster: Randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazoleidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycemic control on metformin treatment with or without a sulfonylurea \u2013 a MASTERMIND study protocol","volume":"10","author":"Angwin","year":"2020","journal-title":"BMJ Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05625-x","article-title":"A novel diabetes typology: Towards precision diabetology from pathogenesis to treatment","volume":"65","author":"Herder","year":"2022","journal-title":"Diabetologia"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1091421\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T15:07:35Z","timestamp":1673363255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1091421\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":26,"alternative-id":["10.3389\/fendo.2022.1091421"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1091421","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1091421"}}